The watchtower for Faith, Family, and Freedom Legislation

Federal HR803: Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

☆ Watch
  1. Introduced
  2. Adopted by House

Overview

This bill urges the FDA to review the safety of chemical abortion drugs (like mifepristone) based on recent independent research, effectively calling for stricter regulation or potential restrictions on medication abortion access.

Law Today

The FDA currently approves mifepristone and other chemical abortion drugs under existing safety protocols and approval standards.

If Passed

This bill does not change law or regulation itself; it urges the FDA to conduct a fresh safety review of chemical abortion drugs based on recent independent research. If the FDA were to comply, it could result in new findings, warnings, or restrictions on these drugs, but the bill itself creates no new legal requirement or prohibition.

AI-generated from the bill text — verify against the official text.

Should I support this?

  1. Strongly Oppose
  2. Likely Oppose
  3. This billNeutral
  4. Likely Support
  5. Strongly Support

Neutral

For Christian families prioritizing protection of unborn life, a call for rigorous safety review may align with pro-life convictions; however, the bill is non-binding and does not guarantee any actual legal change. Christian families concerned about expanding parental oversight in medical decisions or respecting women's health autonomy may view it differently. The practical impact depends entirely on FDA response, making the stance contingent on one's view of chemical abortion itself.

AI assessment using F3’s editorial criteria — faith, family, and freedom. This is F3’s policy judgment; verify the provisions in the official bill text.

Likely supporters & opponents

Likely support

  • pro-life groups and advocacy organizations — Independent studies may reveal safety risks that warrant stricter oversight or withdrawal of approval to protect women's health and unborn life.
  • religious and faith-based organizations — Re-evaluation aligns with moral concerns about chemical abortion and provides opportunity for additional safeguards or restrictions.

Likely opposition

  • abortion-access advocacy organizations and civil-liberties groups — The request is a politically motivated attempt to restrict access to a safe, FDA-approved medication through regulatory pressure rather than sound science.
  • medical and reproductive-health organizations — Chemical abortion drugs have a strong safety record; re-evaluation based on selective studies could undermine evidence-based medicine and women's access to care.

AI-inferred typical positions based on the bill’s substance — general stakeholder categories, not confirmed endorsements.

💬 Chat about this bill ↗Official bill text ↗View on LegiScan ↗

Official summary

Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

Sponsors

  • John Rose (R)
  • Diana Harshbarger (R)
  • Earl Carter (R)
  • Doug LaMalfa (R)
  • Sheri Biggs (R)
  • Barry Moore (R)
  • Harriet Hageman (R)
  • Glenn Grothman (R)
  • Robert Aderholt (R)
  • Andy Harris (R)
  • Michael Guest (R)
  • Ben Cline (R)

Status timeline

  1. 2025-10-10Referred to the House Committee on Energy and Commerce.H
  2. 2025-10-10Submitted in HouseH

H = House · S = Senate · A = Assembly